FDA Grants Accelerated Approval For Breast Cancer Drug

The FDA granted accelerated approval to camizestrant (Etcamah) for first-line treatment of hormone receptor-positive/HER2-negative breast cancer with ESR1 resistance mutations, despite contrary recommendations from agency advisors.

This Wire brief sits within Fusion42's coverage of Biotech, and 14 sources have reported it between 4 Sep 2026 and 9 Sep 2026.